Yoko Edahiro, Tomonori Ochiai, Yoshinori Hashimoto, Michiko Ichii, Takeshi Okatani, Hiromi Omura, Kei Nakajima, Makoto Sasaki, Jun Ando, Tomoiku Takaku, et al. Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan. Hematology (Amsterdam, Netherlands). 2024. 29. 1. 2340149-2340149
Chiho Furuya, Soji Morishita, Yoshinori Hashimoto, Tadaaki Inano, Tomonori Ochiai, Shuichi Shirane, Yoko Edahiro, Marito Araki, Miki Ando, Norio Komatsu. Impact of non-driver gene mutations on thrombo-haemorrhagic events in ET patients. British journal of haematology. 2024. 204. 1. 221-228
Yoko Edahiro, Keita Kirito, Akihiko Gotoh, Katsuto Takenaka, Yuka Sugimoto, Norio Komatsu, Kazuya Shimoda. A cross-sectional survey of symptoms and daily living among patients with polycythemia vera and their treating physicians in Japan. Hematology (Amsterdam, Netherlands). 2023. 28. 1. 2227817-2227817
Chiho Furuya, Yoshinori Hashimoto, Soji Morishita, Tadaaki Inano, Tomonori Ochiai, Shuichi Shirane, Yoko Edahiro, Marito Araki, Miki Ando, Norio Komatsu. MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology (Amsterdam, Netherlands). 2023. 28. 1. 2229131-2229131
杉本 由香, 小松 則夫. 真性多血症におけるロペグインターフェロンアルファ-2bの臨床的有用性 : 科学的エビデンスと臨床経験に基づいた知見-Clinical benefit of ropeginterferon alfa-2b for the patients with polycythemia vera : Based on scientific evidence and clinical experience. 血液内科 = Hematology / 血液内科編集委員会 編. 2023. 87. 5. 588-598
橋本 由徳, 枝廣 陽子, 伊藤 量基, 後藤 明彦, 中前 美佳, 木村 文彦, 小池 道明, 桐戸 敬太, 和田 秀穂, 臼杵 憲祐, et al. A nationwide survey on Japanese patients with essential thrombocythemia: JSH-MPN-R18 study(和訳中). 日本血液学会学術集会. 2021. 83回. OS3-3
安井 寛, 小林 真之, 佐藤 広太, 近藤 幹也, 石田 禎夫, 海渡 裕太, 田村 秀人, 半田 寛, 築根 豊, 佐々木 純, et al. セル・フリーDNAによる多発性骨髄腫の早期再発診断(Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse). International Journal of Myeloma. 2021. 11. 2. 91-91
